Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power.
Ueland
Per Magne
PM
Clarke
Robert
R
D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000235:genetics / Q000517:prevention & control; D003627:Data Interpretation, Statistical; D019587:Dietary Supplements; D004812:Epidemiologic Methods; D019317:Evidence-Based Medicine; D005492:Folic Acid / Q000008:administration & dosage*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D012107:Research Design; D012307:Risk Factors; D018433:Twin Studies as Topic; D014803:Vitamin B Complex / Q000008:administration & dosage
D006710:Homocysteine; D014803:Vitamin B Complex; D005492:Folic Acid; D042965:Methylenetetrahydrofolate Reductase (NADPH2)